Skip to main
NKTX
NKTX logo

Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta, Inc. (NKTX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nkarta Inc. is capitalizing on its innovative allogeneic CAR-NK therapy, which presents significant safety advantages, including potentially lower rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) compared to traditional autologous CAR-T therapies. The company's unique off-the-shelf NK cell manufacturing capability allows for a less cumbersome treatment regimen, which could enhance patient accessibility and adherence, positioning Nkarta favorably in the evolving cancer therapy landscape. With revenues currently projected from lymphomas but also viewing systemic lupus erythematosus (SLE) as potential upside, Nkarta's future studies could further bolster revenue streams contingent on upcoming positive clinical data.

Bears say

Nkarta Inc's stock outlook is negatively influenced by the discontinuation of its NHL development, which has resulted in the removal of these sales from financial models, thereby contributing to a decline in price target from $22 to $18. The company faces significant risks, including potential safety issues in clinical trials, lower-than-expected efficacy, and increased competition, which may adversely affect its clinical programs. Additionally, with an operating loss of $33.8 million in 3Q24 and projected financing needs of approximately $900 million through 2040, Nkarta's financial health may be at risk, indicating concerns regarding its sustainability and growth prospects.

Nkarta, Inc. (NKTX) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nkarta, Inc. (NKTX) Forecast

Analysts have given Nkarta, Inc. (NKTX) a Buy based on their latest research and market trends.

According to 10 analysts, Nkarta, Inc. (NKTX) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nkarta, Inc. (NKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.